Clinical trial · Observational
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study we aim to more precisely define the clinical utility of PSMA imaging across a range of clinical indications in men with prostate cancer. To accomplish this, we will make the 18F-DCFPyL PET/CT scan available to urologists, medical oncologists, and radiation oncologists at Johns Hopkins and survey physicians as to the indication for ordering the PET/CT and if a change in management occurred as the result of new information gained from the scan. We believe these data will prove critical for planning future studies aimed at evaluating the efficacy of this test for improving patient outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F DCFPyL- Radiopharmaceutica | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- adenocarcinoma of the prostate
- interventionNames
- Drug: 18F DCFPyL- Radiopharmaceutica
Primary outcomes (1)
- measure
- Physician responses to a questionnaire
- timeFrame
- less than 1 year
- description
- The Post-PET/CT questionnaire will determine if the PET/CT scan results in changes to clinical management of patient illness.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years 2. Willingness to signed informed consent 3. Histologically confirmed adenocarcinoma of the prostate 4. PSA measurement ≤60 days prior to study enrollment 5. Completed radiographic evaluation with whole-body bone scan (99mTc-MDP or Na18F) and cross-sectional imaging (CT or MRI) of the abdomen and pelvis ≤60 days prior to study enrollment Exclusion Criteria: 1. Administered a radioisotope within 5 physical half-lives prior to study enrollment 2. History of other malignancy diagnosed within the last 5 years (exceptions: low grade urothelial carcinoma of the bladder, squamous cell carcinoma or basal cell carcinoma of the skin).
References
Publications (0)
Data not yet available